

Updated: September 19, 2025

List 1 : Information on Diagnostic Radiopharmaceuticals Approved in Japan for the Purpose of Determining Eligibility of Patients for

Therapeutic Radiopharmaceuticals

Therapeutic Radiopharmaceuticals used with Diagnostic Radiopharmaceuticals				Diagnostic Radiopharmaceuticals			
No.	Proprietary name	Active substance name	Indications	Pharmaceuticals for eligibility determination *		Active substance name	Biomarkers
1	PLUVICTO Injection	Lutetium (^{177}Lu) vipivotide tetraxetan	Prostate cancer	LOCAMETZ Kit	GalliaPharm $^{68}\text{Ge}/^{68}\text{Ga}$ Generator	Gallium (^{68}Ga) gozetotide	Prostate-specific membrane antigen (PSMA)

* When the diagnostic radiopharmaceutical is provided as a preparation kit, the name of the kit is shown in the left column, and the supply method of the radionuclide that can be used for radiolabeling is shown in the right column.